Company Profile

Actavis plc and Forest Laboratories, Inc. announced on February 18, 2014 that they have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at approximately $25 billion. The transaction will create a premier global pharmaceutical leader both in the specialty and primary care arenas. The combination will significantly increase the size of the Actavis Specialty Brands Portfolio to over 30 products principally marketed in the United States, Canada and Europe, and will strengthen the company’s industry-leading pipeline to more than 20 products in various stages of development. We believe we will create a new kind of specialty pharmaceutical company: a specialty pharmaceutical company combining Actavis’ generic DNA with a focus on providing high-quality products efficiently and cost effectively, including an extraordinary array of important specialty branded products, a worldwide portfolio of generic products, OTC products and ultimately biosimilar products to our global customer base. When combined with the expansive 60+ market global commercial powerhouse of Actavis Pharma and the industry-leading manufacturing capabilities of Actavis Global Operations, Actavis and Forest will operate a truly formidable pharmaceutical company – and continue to drive exceptional value for our shareholders, customers and employees. The per share consideration represents a premium of approximately 25 percent per share over Forest's stock price, and a premium of approximately 31 percent over Forest's 10-day volume weighted average stock price, as of the close of trading on February 14, 2014. If successfully completed, the transaction will combine two of the world's fastest-growing specialty pharmaceutical companies, with combined annual revenues of over $15 billion anticipated for 2015.